MBP and stroke disorder: Th1 responses against MBP ranged from 24% in patients with no stroke-associated infection to 60% in patients with pneumonia and more robust Th1 responses to MBP 90 days after human stroke were associated with a decreased likelihood of good functional outcome, even after adjusting for major independent prognostic factors such as baseline stroke severity and age.